Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought By: MarketWatch March 16, 2017 at 15:40 PM EDT Analyst asks: What choice does PTC Therapeutics have but to “dramatically” lower the price? Read More >> Related Stocks: Gilead Sciences Mylan Pfizer Ptc Therapeutics Sarepta Therapeutics Valeant Pharmaceuticals International, Inc.